Caris Life Sciences, Inc. (CAI)

Caris Life Sciences, Inc. is a precision medicine company headquartered in Irving, Texas, that provides molecular profiling services mainly for cancer. The company completed its initial public offering on the Nasdaq in 2025.

Caris analyzes tumor tissue and blood samples using whole exome and whole transcriptome sequencing, along with other molecular techniques, to give oncologists detailed information about a patient's cancer. Its tissue-based tumor profiling and blood-based liquid biopsy tests help physicians select targeted therapies and immunotherapies and identify relevant clinical trials. The company also uses its large database of molecular and clinical outcomes data, combined with artificial intelligence, to support research and to partner with biopharmaceutical companies on drug development and trial recruitment.